

PRESS RELEASE



ExonHit's 2009 Ordinary Annual Meeting

- Shareholders approved all resolutions proposed by ExonHit's Management Board
- Renewal of the mandate of ExonHit's Management Board members

Paris, France – April 28, 2009 – At the Ordinary Annual Meeting held on April 24th 2009, ExonHit's shareholders approved all resolutions proposed by the Management Board.

The shareholders have specifically:

- approved both the parent company's and the group consolidated financial statements for 2008
- renewed the mandate of Christophe Jean as Member of the Supervisory Board
- approved a share buyback program to be used as part of a liquidity contract

An Extraordinary Meeting will be held, following a second convening on Wednesday, May 6th 2009, at 10:30 am CET, at the Company's headquarters in Paris (63-65 Bd Masséna, 75013 Paris).

Immediately following the Ordinary Annual Meeting, the Supervisory Board renewed for a three year term, i.e. until the end of the Annual Meeting which will be held to approve the 2011 financial statements:

- the mandate of Dr. Loïc Maurel as Member and President of the Management Board
- the mandate of John Jaskowiak, Executive Vice President, Molecular Diagnostic & Genomic Services, as Member of the Management Board
- the mandate of Matthew Pando, Executive Vice President, Therapeutics, as Member of the Management Board

The mandate of Member of the Management Board of Philippe Rousseau was not renewed. He is Chief Financial Officer of the Company.

About ExonHit Therapeutics

ExonHit Therapeutics (Alternext: ALEHT) is a fast emerging healthcare player active in both therapeutics and diagnostics. The Company is applying its proprietary technology, based on the analysis of alternative RNA splicing, to develop innovative blood based diagnostic tests and therapeutics for neurodegenerative and cancer indications. ExonHit has a balanced investment strategy with internal development programs and strategic collaborations, in particular with bioMérieux and Allergan.

ExonHit is headquartered in Paris, France and has U.S. offices in Gaithersburg, Maryland. The Company is listed on Alternext of NYSE Euronext Paris. For more information, please visit <http://www.exonhit.com>.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements on future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.

ExonHit Therapeutics**Media Contact**

Corinne Hoff
+33 1 58 05 47 04
corinne.hoff@exonhit.com

Investor Contact

Philippe Rousseau, CFO
+1 240 404 0191
philippe.rousseau@exonhit.com